{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:20:15Z","timestamp":1788254415130,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11060-026-05743-9","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:11:55Z","timestamp":1786111915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinguishing true progression from treatment effects in glioblastoma: a practical, evidence-graded imaging framework for the multidisciplinary team"],"prefix":"10.1007","volume":"179","author":[{"given":"Chirag B.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia C.","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Ginat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Moliterno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7724-5784","authenticated-orcid":false,"given":"Jason M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"8","key":"5743_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251","journal-title":"Neuro Oncol"},{"issue":"10","key":"5743_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, van den Mason WP et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996","journal-title":"N Engl J Med"},{"issue":"5","key":"5743_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","volume":"9","author":"D Brandsma","year":"2008","unstructured":"Brandsma D, Stalpers L, Taal W, van den Sminia P (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453\u2013461","journal-title":"Lancet Oncol"},{"issue":"3","key":"5743_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00062-017-0584-x","volume":"28","author":"AW Abbasi","year":"2018","unstructured":"Abbasi AW, Westerlaan HE, Holtman GA et al (2018) Incidence of tumour progression and pseudoprogression in high-grade gliomas: a systematic review and meta-analysis. Clin Neuroradiol 28(3):401\u2013411","journal-title":"Clin Neuroradiol"},{"issue":"3","key":"5743_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11060-017-2375-2","volume":"134","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ (2017) Pseudoprogression, radionecrosis, inflammation or true tumor progression? J Neurooncol 134(3):495\u2013504","journal-title":"J Neurooncol"},{"issue":"13","key":"5743_CR6","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","volume":"26","author":"AA Brandes","year":"2008","unstructured":"Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192\u20132197","journal-title":"J Clin Oncol"},{"issue":"4","key":"5743_CR7","doi-asserted-by":"publisher","first-page":"101044","DOI":"10.1016\/j.adro.2022.101044","volume":"7","author":"J Bronk","year":"2022","unstructured":"Bronk J, Amer A, Khose S et al (2022) Brain radiation necrosis outside the target volume after proton radiation therapy. Adv Radiat Oncol 7(4):101044","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"5743_CR8","first-page":"1","volume":"26","author":"TJC Wang","year":"2024","unstructured":"Wang TJC, Jani A, Estrada JP et al (2024) Radiation necrosis as a complication after radiation therapy for primary brain tumors and brain metastases. Curr Treat Options Neurol 26(1):1\u201318","journal-title":"Curr Treat Options Neurol"},{"issue":"6","key":"5743_CR9","first-page":"892","volume":"85","author":"S Acharya","year":"2019","unstructured":"Acharya S, Robinson CG, Michalski JM et al (2019) Risk of symptomatic radiation necrosis in patients treated with stereotactic radiosurgery for brain metastases. Neurosurgery 85(6):892\u2013900","journal-title":"Neurosurgery"},{"issue":"10","key":"5743_CR10","first-page":"1101","volume":"44","author":"N Soni","year":"2023","unstructured":"Soni N, Ora M, Mohindra N, Menda Y, Bathla G (2023) Amino acid PET-MRI in glioma management: a systematic review and critical appraisal. AJNR Am J Neuroradiol 44(10):1101\u20131110","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"5743_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/neuonc\/noz003","volume":"21","author":"N Galldiks","year":"2019","unstructured":"Galldiks N, Langen KJ, Albert NL et al (2019) PET imaging in patients with brain metastasis: report of the RANO\/PET group. Neuro Oncol 21(5):585\u2013595","journal-title":"Neuro Oncol"},{"issue":"6","key":"5743_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/neuonc\/noab013","volume":"23","author":"N Galldiks","year":"2021","unstructured":"Galldiks N, Niyazi M, Grosu AL et al (2021) Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients. Neuro Oncol 23(6):881\u2013893","journal-title":"Neuro Oncol"},{"issue":"3","key":"5743_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s11060-025-05146-2","volume":"175","author":"S Dagher","year":"2025","unstructured":"Dagher S, Johnson JM, Mohamed R et al (2025) Study of \u00b9\u2078F-fluciclovine PET for serial assessment of glioblastoma tumor volumes during surgery and radiotherapy. J Neurooncol 175(3):549\u2013560","journal-title":"J Neurooncol"},{"issue":"6","key":"5743_CR14","doi-asserted-by":"publisher","first-page":"852","DOI":"10.2967\/jnumed.122.264812","volume":"64","author":"A Nabavizadeh","year":"2023","unstructured":"Nabavizadeh A, Bagley SJ, Doot RK et al (2023) Distinguishing progression from pseudoprogression in glioblastoma using \u00b9\u2078F-fluciclovine PET. J Nucl Med 64(6):852\u2013858","journal-title":"J Nucl Med"},{"issue":"6","key":"5743_CR15","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3174\/ajnr.A9120","volume":"47","author":"J Ivanidze","year":"2026","unstructured":"Ivanidze J, Vu KV, Fu R et al (2026) Clinical utility of [\u00b9\u2078F]-fluciclovine PET\/MRI for differentiating true progression from treatment-related changes in patients with glioblastoma. AJNR Am J Neuroradiol 47(6):1578\u20131586. https:\/\/doi.org\/10.3174\/ajnr.A9120","journal-title":"AJNR Am J Neuroradiol"},{"issue":"9","key":"5743_CR16","first-page":"1188","volume":"17","author":"BM Ellingson","year":"2015","unstructured":"Ellingson BM, Bendszus M, Boxerman J et al (2015) Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro Oncol 17(9):1188\u20131198","journal-title":"Neuro Oncol"},{"issue":"11","key":"5743_CR17","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963\u20131972","journal-title":"J Clin Oncol"},{"issue":"15","key":"5743_CR18","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16(15):e534\u2013e542","journal-title":"Lancet Oncol"},{"issue":"2","key":"5743_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14(2):307\u2013320","journal-title":"Neurotherapeutics"},{"issue":"17","key":"5743_CR20","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1200\/JCO.22.01579","volume":"41","author":"G Youssef","year":"2023","unstructured":"Youssef G, Rahman R, Bay C et al (2023) Evaluation of standard, modified, and immunotherapy response assessment in neuro-oncology in newly diagnosed and recurrent glioblastoma. J Clin Oncol 41(17):3160\u20133171","journal-title":"J Clin Oncol"},{"issue":"33","key":"5743_CR21","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY van den Wen","year":"2023","unstructured":"van den Wen PY, Youssef G et al (2023) RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 41(33):5187\u20135199","journal-title":"J Clin Oncol"},{"issue":"10","key":"5743_CR22","first-page":"1862","volume":"26","author":"BM Ellingson","year":"2024","unstructured":"Ellingson BM, Hatae R, Telesca D et al (2024) Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas. Neuro Oncol 26(10):1862\u20131873","journal-title":"Neuro Oncol"},{"issue":"1","key":"5743_CR23","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","volume":"25","author":"NL Albert","year":"2024","unstructured":"Albert NL, Galldiks N, Ellingson BM et al (2024) PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol 25(1):e29\u2013e41","journal-title":"Lancet Oncol"},{"issue":"8","key":"5743_CR24","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1016\/S1470-2045(25)00193-7","volume":"26","author":"N Galldiks","year":"2025","unstructured":"Galldiks N, Lohmann P, Aboian M et al (2025) Update to the RANO\/EANO recommendations for the clinical use of PET imaging in gliomas. Lancet Oncol 26(8):e436\u2013e447","journal-title":"Lancet Oncol"},{"issue":"5","key":"5743_CR25","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41591-025-03633-7","volume":"31","author":"NL Albert","year":"2025","unstructured":"Albert NL, Galldiks N, Ellingson BM et al (2025) RANO criteria for response assessment of brain metastasis based on amino acid PET imaging. Nat Med 31(5):1424\u20131430","journal-title":"Nat Med"},{"issue":"5","key":"5743_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/neuonc\/nos307","volume":"15","author":"N Verma","year":"2013","unstructured":"Verma N, Cowperthwaite MC, Burnett MG, Markey MK (2013) Differentiating tumor recurrence from treatment necrosis. Neuro Oncol 15(5):515\u2013534","journal-title":"Neuro Oncol"},{"issue":"1","key":"5743_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/neuonc\/now148","volume":"19","author":"P Patel","year":"2017","unstructured":"Patel P, Baradaran H, Delgado D et al (2017) MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment. Neuro Oncol 19(1):118\u2013127","journal-title":"Neuro Oncol"},{"issue":"10","key":"5743_CR28","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1007\/s00330-017-4789-9","volume":"27","author":"BRJ van Dijken","year":"2017","unstructured":"van Dijken BRJ, van Laar PJ, van der Holtman GA (2017) Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma. Eur Radiol 27(10):4129\u20134144","journal-title":"Eur Radiol"},{"issue":"6","key":"5743_CR29","first-page":"745","volume":"45","author":"G Yamin","year":"2024","unstructured":"Yamin G, Schwartz KM, Hagiwara M et al (2024) Impact of arterial spin labeling and dynamic susceptibility contrast perfusion on clinical decision-making in patients with treated high-grade glioma. AJNR Am J Neuroradiol 45(6):745\u2013751","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"5743_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2214\/AJR.17.18003","volume":"210","author":"K Nael","year":"2018","unstructured":"Nael K, Bauer AH, Howlader R et al (2018) Multiparametric MRI for differentiation of radiation necrosis from recurrent tumor in patients with treated glioblastoma. AJR Am J Roentgenol 210(1):18\u201323","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"5743_CR31","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/RCT.0000000000001716","volume":"49","author":"A Amer","year":"2025","unstructured":"Amer A, Ansari S, Krayyem A et al (2025) Dynamic contrast-enhanced MRI processing comparison for distinguishing true progression from pseudoprogression in high-grade glioma. J Comput Assist Tomogr 49(5):656\u2013661","journal-title":"J Comput Assist Tomogr"},{"issue":"5","key":"5743_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrneurol.2017.44","volume":"13","author":"KJ Langen","year":"2017","unstructured":"Langen KJ, Galldiks N, Hattingen E, Shah NJ (2017) Advances in neuro-oncology imaging. Nat Rev Neurol 13(5):279\u2013289","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"5743_CR33","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ejrad.2014.09.018","volume":"83","author":"H Zhang","year":"2014","unstructured":"Zhang H, Ma L, Wang Q et al (2014) Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis. Eur J Radiol 83(12):2181\u20132189","journal-title":"Eur J Radiol"},{"issue":"2","key":"5743_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/jmri.26645","volume":"50","author":"J Zhou","year":"2019","unstructured":"Zhou J, Heo HY, Knutsson L, van Zijl PCM, Jiang S (2019) APT-weighted MRI: techniques, current neuro applications, and challenging issues. J Magn Reson Imaging 50(2):347\u2013364","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"5743_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/neuonc\/nou230","volume":"17","author":"L Zach","year":"2015","unstructured":"Zach L, Guez D, Last D et al (2015) Delayed contrast extravasation MRI: a new paradigm in neuro-oncology. Neuro Oncol 17(3):457\u2013465","journal-title":"Neuro Oncol"},{"issue":"2","key":"5743_CR36","doi-asserted-by":"publisher","first-page":"100424","DOI":"10.1016\/j.esmoop.2022.100424","volume":"7","author":"R Bodensohn","year":"2022","unstructured":"Bodensohn R, Forbrig R, Quach S et al (2022) MRI-based contrast clearance analysis shows high differentiation accuracy between radiation-induced reactions and progressive disease after cranial radiotherapy. ESMO Open 7(2):100424","journal-title":"ESMO Open"},{"issue":"1","key":"5743_CR37","doi-asserted-by":"publisher","first-page":"vdaf161","DOI":"10.1093\/noajnl\/vdaf161","volume":"7","author":"M Tahamtan","year":"2025","unstructured":"Tahamtan M, Afsharzadeh M, Sarvari M et al (2025) Contrast clearance analysis in neuro-oncology: a systematic review and meta-analysis on differentiating posttreatment changes from tumor progression. Neurooncol Adv 7(1):vdaf161. https:\/\/doi.org\/10.1093\/noajnl\/vdaf161","journal-title":"Neurooncol Adv"},{"issue":"4","key":"5743_CR38","doi-asserted-by":"publisher","first-page":"e2431595","DOI":"10.2214\/AJR.24.31595","volume":"223","author":"SA Dagher","year":"2024","unstructured":"Dagher SA, Liu HL, Ozkara BB et al (2024) The impact of MRI-based advanced neuroimaging on neurooncologists\u2019 clinical decision-making in patients with posttreatment high-grade glioma: a prospective survey-based study. AJR Am J Roentgenol 223(4):e2431595. https:\/\/doi.org\/10.2214\/AJR.24.31595","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"5743_CR39","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1016\/j.prro.2024.04.009","volume":"14","author":"D Yadav","year":"2024","unstructured":"Yadav D, Upadhyay R, Kumar V et al (2024) Additive value of magnetic resonance simulation before chemoradiation in evaluating treatment response and pseudoprogression in high-grade gliomas. Pract Radiat Oncol 14(5):e449\u2013e457","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"5743_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/bioengineering5040104","volume":"5","author":"A Najjar","year":"2018","unstructured":"Najjar A, Johnson JM, Schellingerhout D (2018) The emerging role of amino acid PET in neuro-oncology. Bioengineering 5(4):104","journal-title":"Bioengineering"},{"issue":"9","key":"5743_CR41","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/neuonc\/now058","volume":"18","author":"NL Albert","year":"2016","unstructured":"Albert NL, Weller M, Suchorska B et al (2016) Response Assessment in Neuro-Oncology working group and EANO recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 18(9):1199\u20131208","journal-title":"Neuro Oncol"},{"issue":"3","key":"5743_CR42","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","volume":"46","author":"I Law","year":"2019","unstructured":"Law I, Albert NL, Arbizu J et al (2019) Joint EANM\/EANO\/RANO practice guidelines for imaging of gliomas using PET with radiolabelled amino acids. Eur J Nucl Med Mol Imaging 46(3):540\u2013557","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5743_CR43","doi-asserted-by":"publisher","first-page":"740280","DOI":"10.3389\/fneur.2021.740280","volume":"12","author":"JM Johnson","year":"2021","unstructured":"Johnson JM, Chen M, Rohren E et al (2021) Delayed FDG PET provides superior glioblastoma conspicuity compared to conventional image timing. Front Neurol 12:740280","journal-title":"Front Neurol"},{"issue":"3","key":"5743_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/neuonc\/nos300","volume":"15","author":"M Hutterer","year":"2013","unstructured":"Hutterer M, Nowosielski M, Putzer D et al (2013) [\u00b9\u2078F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology. Neuro Oncol 15(3):341\u2013351","journal-title":"Neuro Oncol"},{"key":"5743_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejrad.2018.04.003","volume":"103","author":"T Pyka","year":"2018","unstructured":"Pyka T, Hiob D, Preibisch C et al (2018) Diagnosis of glioma recurrence using multiparametric dynamic \u00b9\u2078F-fluoroethyl-tyrosine PET-MRI. Eur J Radiol 103:32\u201337","journal-title":"Eur J Radiol"},{"issue":"6","key":"5743_CR46","first-page":"904","volume":"47","author":"W Chen","year":"2006","unstructured":"Chen W, Silverman DHS, Delaloye S et al (2006) \u00b9\u2078F-FDOPA PET imaging of brain tumors: comparison study with \u00b9\u2078F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47(6):904\u2013911","journal-title":"J Nucl Med"},{"issue":"7","key":"5743_CR47","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nrneurol.2016.80","volume":"12","author":"KJ Langen","year":"2016","unstructured":"Langen KJ, Watts C (2016) Neuro-oncology: amino acid PET for brain tumours\u2014ready for the clinic? Nat Rev Neurol 12(7):375\u2013376","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"5743_CR48","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/neuonc\/now154","volume":"18","author":"S Kebir","year":"2016","unstructured":"Kebir S, Rauschenbach L, Galldiks N et al (2016) Dynamic O-(2-[\u00b9\u2078F]fluoroethyl)-L-tyrosine PET for the detection of checkpoint inhibitor-related pseudoprogression. Neuro Oncol 18(10):1462\u20131464","journal-title":"Neuro Oncol"},{"issue":"8","key":"5743_CR49","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s00259-013-2403-1","volume":"40","author":"BJ McParland","year":"2013","unstructured":"McParland BJ, Wall A, Johansson S, S\u00f6rensen J (2013) The clinical safety, biodistribution and internal radiation dosimetry of [\u00b9\u2078F]fluciclovine in healthy adult volunteers. Eur J Nucl Med Mol Imaging 40(8):1256\u20131264","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"5743_CR50","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00259-018-4188-8","volume":"46","author":"P Lohmann","year":"2019","unstructured":"Lohmann P, Stavrinou P, Lipber K et al (2019) FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging 46(3):591\u2013602","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5743_CR51","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00259-015-3183-6","volume":"43","author":"OM Henriksen","year":"2016","unstructured":"Henriksen OM, M\u00f8ller Larsen V, Muhic A et al (2016) Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [\u00b9\u2078F]-fluoroethyltyrosine PET\/MRI. Eur J Nucl Med Mol Imaging 43(1):103\u2013112","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"5743_CR52","doi-asserted-by":"publisher","first-page":"e0176528","DOI":"10.1371\/journal.pone.0176528","volume":"12","author":"TC Booth","year":"2017","unstructured":"Booth TC, Larkin TJ, Yuan Y et al (2017) Analysis of heterogeneity in T2-weighted MR images can differentiate pseudoprogression from progression in glioblastoma. PLoS ONE 12(5):e0176528","journal-title":"PLoS ONE"},{"issue":"2","key":"5743_CR53","first-page":"e232231","volume":"310","author":"TC Booth","year":"2024","unstructured":"Booth TC, Thompson G, Garriga C et al (2024) Machine learning and glioma imaging biomarkers: a systematic review. Radiology 310(2):e232231","journal-title":"Radiology"},{"issue":"1","key":"5743_CR54","doi-asserted-by":"publisher","first-page":"e220231","DOI":"10.1148\/ryai.220231","volume":"6","author":"K Hoebel","year":"2024","unstructured":"Hoebel K, Bridge C, Ahmed S et al (2024) Expert-centered evaluation of deep learning algorithms for brain tumor segmentation. Radiol Artif Intell 6(1):e220231","journal-title":"Radiol Artif Intell"},{"issue":"2","key":"5743_CR55","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3171\/jns.2006.104.2.238","volume":"104","author":"B Pirotte","year":"2006","unstructured":"Pirotte B, Goldman S, Dewitte O et al (2006) Integrated PET and MRI-guided resection of brain tumors. J Neurosurg 104(2):238\u2013253","journal-title":"J Neurosurg"},{"issue":"Suppl 3","key":"5743_CR56","first-page":"iii4","volume":"3","author":"D Barboriak","year":"2021","unstructured":"Barboriak D, Steingrimsson J, Gatsonis C, Schiff D, Kleinberg L (2021) Increasing efficiency in early phase multicenter imaging biomarker trials: emerging strategies from the GABLE trial. Neurooncol Adv 3(Suppl 3):iii4","journal-title":"Neurooncol Adv"},{"key":"5743_CR57","unstructured":"ClinicalTrials.gov. MR-guided radiation therapy for glioblastoma (MARGA). NCT05565326. Accessed April 2026. https:\/\/clinicaltrials.gov\/study\/NCT05565326"},{"key":"5743_CR58","unstructured":"ClinicalTrials.gov. Quantitative [\u00b9\u2078F]FLT-PET and advanced MRI in glioblastoma. NCT01880008. Accessed April 2026. https:\/\/clinicaltrials.gov\/study\/NCT01880008"},{"issue":"224","key":"5743_CR59","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224ra24","journal-title":"Sci Transl Med"},{"issue":"4","key":"5743_CR60","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nm.2682","volume":"18","author":"C Choi","year":"2012","unstructured":"Choi C, Ganji SK, DeBerardinis RJ et al (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients. Nat Med 18(4):624\u2013629","journal-title":"Nat Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05743-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:02:19Z","timestamp":1788253339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05743-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5743"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05743-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a narrative review of previously published literature; no new patient data were collected and no institutional review board approval was required. Representative images were obtained as part of routine clinical care and fully de-identified.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.M.J. has previously received research support from Blue Earth Diagnostics for a study investigating\n                      18\n                      F-fluciclovine PET\/CT for glioblastoma tumor volume and radiation-response assessment (Principal Investigator). The remaining authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"34"}}